Abstract:Tuberculosis (TB) remains a global health threat of alarming proportions, resulting in 1.5 million deaths worldwide. The only available licensed vaccine, Bacillus Calmette-Guérin, does not confer lifelong protection against active TB. To date, development of an effective vaccine against TB has proven to be elusive, and devising newer approaches for improved vaccination outcomes is an essential goal. Insights gained over the last several years have revealed multiple mechanisms of immune manipulation by Mycobacterium tuberculosis (Mtb) in infected macrophages and dendritic cells that support disease progression and block development of protective immunity. This review provides an assessment of the known immunoregulatory mechanisms altered by Mtb, and how new interventions may reverse these effects. Examples include blocking of inhibitory immune cell coreceptor checkpoints (e.g., programed death-1). Conversely, immune mechanisms that strengthen immune cell effector functions may be enhanced by interventions, including stimulatory immune cell coreceptors (e.g., OX40). Modification of the activity of key cell "immunometabolism" signaling pathway molecules, including mechanistic target of rapamycin, glycogen synthase kinase-3β, wnt/β-catenin, adenosine monophosophate-activated protein kinase, and sirtuins, related epigenetic changes, and preventing induction of immune regulatory cells (e.g., regulatory T cells, myeloid-derived suppressor cells) are powerful new approaches to improve vaccine responses. Interventions to favorably modulate these components have been studied primarily in oncology to induce efficient antitumor immune responses, often by potentiation of cancer vaccines. These agents include antibodies and a rapidly increasing number of small molecule drug classes that have contributed to the dramatic immune-based advances in treatment of cancer and other diseases. Because immune responses to malignancies and to Mtb share many similar mechanisms, studies to improve TB vaccine responses using interventions based on "immuno-oncology" are needed to guide possible repurposing. Understanding the regulation of immune cell functions appropriated by Mtb to promote the imbalance between protective and pathogenic immune responses may guide the development of innovative drug-based adjunct approaches to substantially enhance the clinical efficacy of TB vaccines.

From Antigens to Immune Responses: Shaping the Future of TB Detection and Prevention

Induction of an Immune-Protective T-Cell Repertoire with Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans

New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity

Antibodies as key mediators of protection against Mycobacterium tuberculosis

Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection

Tuberculosis: Current state of knowledge: An Epilogue

Antigen specificity shapes antibody functions in tuberculosis.

Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens

Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development

Analysis of the Antigenic Properties of Membrane Proteins of Mycobacterium Tuberculosis

Recent Advances in the Development of Protein- and Peptide-Based Subunit Vaccines against Tuberculosis

Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development

Immunopeptidomics informs discovery and delivery of Mycobacterium tuberculosis MHC-II antigens for vaccine design

Exploration of novel cellular and serological antigen biomarkers in the ORFeome of Mycobacterium tuberculosis.

Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination

Proteomics-based host-specific biomarkers for tuberculosis: The future of TB diagnosis

It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity

Therapy modulates the response to T cell epitopes over the spectrum of tuberculosis infection

Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches

Immunoproteomic Identification of Human T Cell Antigens of Mycobacterium Tuberculosis That Differentiate Healthy Contacts from Tuberculosis Patients

In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination